Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
This is a phase I/II, open-Label, dose-Escalation and dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in combination with Toripalimab in Advanced Solid Tumours.
Advanced Solid Tumor
DRUG: LM-108|DRUG: Toripalimab
Incidence of adverse events (AEs), 152 Weeks|Incidence of dose-limiting toxicity (DLT), 152 Weeks|Incidence of serious adverse event (SAE), 152 Weeks|Incidence of clinical significant in laboratory examinations, including hematology, urinalysis, blood biochemistry, coagulation tests and thyroid function., 152 Weeks
Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax) for LM-108, 152 Weeks|PK Parameter: Time of Maximum Observed Concentration (Tmax) for LM-108, 152 Weeks|PK Parameter: Area Under the Concentration-time Curve (AUC) for LM-108, 152 Weeks|PK Parameter: Steady State Maximum Concentration (Cmax,ss), 152 Weeks|PK Parameter: Steady State Minimum Concentration (Cmin, ss), 152 Weeks|PK Parameter: Systemic Clearance at Steady State (CLss), 152 Weeks|PK Parameter: Accumulation Ratio (Rac), 152 Weeks|PK Parameter: Elimination Half-life (t 1/2), 152 Weeks|PK Parameter: Volume of Distribution at Steady-State (Vss), 152 Weeks|PK Parameter: Degree of Fluctuation (DF), 152 Weeks|Incidence of anti-drug antibodies to LM-108, 152 Weeks
This is a phase I/II, open-Label, dose-Escalation and dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in combination with Toripalimab in Advanced Solid Tumours.